Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC By Ogkologos - April 15, 2025 325 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUNNIFORECAST study Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer February 20, 2024 Los obstáculos en la atención para las personas LGBTQ con cáncer:... January 21, 2021 FDA Approves HPV Tests That Allow for Self-Collection in a Health... July 24, 2024 Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... November 7, 2024 Load more HOT NEWS New on NCI’s Websites for June 2023 Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09
